Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
- COVID-19
- Seasonal Influenza
Jun 14, 2021
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
- COVID-19
- Seasonal Influenza
May 10, 2021
Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure
- Seasonal Influenza
Oct 13, 2020
Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
- Seasonal Influenza
Mar 24, 2020
Novavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity
- Seasonal Influenza
Feb 25, 2020
Novavax Granted Fast Track Designation for NanoFlu in Older Adults
- Seasonal Influenza
Jan 15, 2020
Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults
- Seasonal Influenza
Oct 15, 2019
Novavax Reaches Agreement with the FDA on Pivotal Phase 3 Trial Design for NanoFlu
- Seasonal Influenza
Aug 5, 2019
Novavax Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu™
- Seasonal Influenza
Jun 27, 2019
Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention
- Seasonal Influenza
Jun 4, 2019

Show per page